Doxazosin - Benign prostatic hyperplasia
You are here : Home > Formulary Search > Doxazosin - Benign prostatic hyperplasia
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green
Formulations :
- Immediate release tablets
Formulary Status :
Restrictions / Comments :
Preferred
Status 2
Non Formulary
Formulations :
- Modified release tablets
Formulary Status :
Restrictions / Comments :
Important
Use immediate release tablets
Do not initiate in new patients.
Review in current patients. If doxazosin remains the best option, switch to immediate release tablets in line with NHS England guidance.
Documents :
Guidelines (National)
Policy Statement
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Doxazosin
Indication :
Benign prostatic hyperplasia
Group Name :
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Cardura, Doxadura
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4
Traffic Light Entries :
2
Other Indications
Below are listed other indications that Doxazosin is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Benign prostatic hyperplasia.
Committee Recommendations (1)
Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option
- Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
- Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)
Alfuzosin is more costly and is therefore not recommended as a 1st-line option.
Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups
- Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
- Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)
Alfuzosin is more costly and is therefore not recommended as a 1st-line option.
Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups